Association of PD1 and TIM3 polymorphisms with HBV susceptibility

Huang, Claire E.; Xia, Chan; Zhu, Huanling; Wo, John M.; Chen, F.; Zheng, Min; Chen, Z.

doi:10.1016/s0168-8278(18)31877-4

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After literature review, 13 SNPs with reported associations with diseases or phenotypes were retrieved, including one missense polymorphism ( rs2227982 ) and one synonymous polymorphism ( rs2227981 ) (Table ). However, only nine SNPs ( rs36084323 , rs6747063 , rs6758577 , rs7419870 , rs41386349 , rs6705653 , rs2227982 , rs2227981 and rs10204525 ) had minor allele frequency > 20% in 1000 Genomes ASN panel (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, previous studies indicate that PDCD1 deficiency has functional consequences for arthritis severity, autoantibody formation and resistance to treatment, suggesting that PDCD1 is involved in arthritis severity, autoantibody production and response to treatments. In addition, several PDCD1 polymorphisms have been associated with chronic viral infection, including subacute sclerosing panencephalitis and hepatitis B infection . Therefore, PDCD1 polymorphisms could potentially be associated with RA autoantibody status and the patient's response to treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic and epigenetic alteration of the programmed cell death 1 in rheumatoid arthritis

Tseng

Lin

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is an autoimmune disease where both genetics and epigenetics are contributing factors. In order to discover genetic and epigenetic associations with RA and its phenotypes, we analysed RNA expression, DNA variations and DNA methylation of programmed cell death 1 (PDCD1) in a cohort of RA patients and healthy controls. Methods RA patients (n = 206) and healthy controls (n = 234) were included for analysis of PDCD1 expression, PDCD1 polymorphisms and PDCD1 methylation. Differences in continuous variables between groups were compared by applying t tests. Associations between phenotypes and genotypes were evaluated with contingency tables. Sensitivity analyses were conducted to confirm the robustness of results, considering potential confounding factors and different treatment response definitions. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Results Higher expression of PDCD1 was found in RA compared to controls (P < 0.001), with similar PDCD1 polymorphisms in RA and controls. rs36084323 decreased inadequate response to conventional synthetic disease‐modifying antirheumatic drugs (OR = 0.37, 95% CI = 0.19‐0.72, P = 0.003), and rs41386349 increased rheumatoid factor seropositivity (OR = 11.89, 95% CI = 1.57‐89.87, P = 0.003). Sensitivity analysis adjusting for further potential confounders and using different treatment response definition indicated similar results. Additionally, DNA methylation change at regulatory region of PDCD1 was detected in RA (P = 0.036). Conclusion Altogether, this was the first study to suggest genetic and epigenetic changes of PDCD1 in RA subsets and RA. Independent prospective cohorts are awaited to address the implications of these genetic and epigenetic changes in disease pathogenesis and phenotypes of RA.

show abstract

Section: Resultsmentioning

confidence: 99%